12:38 Tue 02 Mar 2021
Redx Pharma plc - Result of AGM and Directorate change
REDX PHARMA PLC
("Redx" or "the Company")
Result of Annual General Meeting and Directorate change
The table below sets out the details of the votes put to shareholders
Resolution numbe |
Resolution name |
Number of votes for & discretionary |
% of votes for & discretionary |
Number of votes against |
% of votes against |
% of votes witheld |
Total votes cast (including withheld) |
1 |
Receive the Company's annual accounts |
247,031,884 |
94.79% |
13,571,429 |
5.21% |
0.00% |
260,604,013 |
2 |
Re-appoint RSM as auditors |
260,597,840 |
100% |
200 |
0.00% |
0.00% |
260,604,013 |
3 |
Elect |
260,597,840 |
100% |
200 |
0.00% |
0.00% |
260,604,013 |
4 |
Elect Dr |
260,597,840 |
100% |
200 |
0.00% |
0.00% |
260,604,013 |
5 |
Re-elect |
260,603,513 |
100% |
0 |
0.00% |
0.00% |
260,604,013 |
6 |
Re-elect Dr |
260,598,040 |
100% |
0 |
0.00% |
0.00% |
260,604,013 |
7 |
Re-elect |
260,603,513 |
100% |
0 |
0.00% |
0.00% |
260,604,013 |
8 |
Authorise the directors to allot shares |
260,594,551 |
100% |
1,686 |
0.00% |
0.00% |
260,604,013 |
9 |
Disapply pre-emption rights |
260,594,551 |
100% |
2,389 |
0.00% |
0.00% |
260,604,013 |
The Chairman,
"As the Company continues to progress its pipeline and expand its operations, the Board has reviewed its composition and that of the executive leadership team. As a result, a search for a US based Chief Financial Officer has been initiated.
For further information, please contact: |
|
|
|
Redx Pharma Plc |
T: +44 1625 469 918 |
|
|
|
|
SPARK Advisory Partners (Nominated Adviser) |
T: +44 203 368 3550 |
|
|
|
|
WG Partners LLP (Broker) |
T: +44 20 3705 9330 |
Claes Spång/ |
|
|
|
|
|
FTI Consulting |
T: +44 20 3727 1000 |
|
|
|
|
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE